NCT02024555View on ClinicalTrials.gov

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

April 1, 2019

Study Completion Date

April 1, 2019

Conditions
Sarcoidosis; Antimycobacterial Therapy
Interventions
DRUG

Levofloxacin

DRUG

Ethambutol

DRUG

Azithromycin

DRUG

Rifampin

DRUG

Placebo

This will serve as a placebo to the antibiotics used in antimycobacterial therapy.

Trial Locations (6)

12208

Albany Medical Center, Albany

29425

Medical University of South Carolina, Charleston

37232

Vanderbilt University School of Medicine, Nashville

43221

Ohio State University, Columbus

44195

Cleveland Clinic, Cleveland

45267

University of Cincinnati, Cincinnati

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Vanderbilt University

OTHER

NCT02024555 - Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis | Biotech Hunter | Biotech Hunter